查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2088875

下一代癌症診斷市場：2026-2032年全球市場預測（按產品類型、技術、癌症類型、檢體類型和應用分類）

Next-Generation Cancer Diagnostics Market by Product, Technology, Cancer Type, Sample Type, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，下一代癌症診斷市場將成長至 370.5 億美元，複合年成長率為 11.26%。

主要市場統計數據
基準年 2025 175.5億美元
預計年份：2026年 195億美元
預測年份 2032 370.5億美元
複合年成長率 (%) 11.26%

新一代癌症診斷技術正在重新定義腫瘤學，它將檢測、腫瘤分類、治療選擇和復發監測與近乎即時的臨床決策聯繫起來。此領域涵蓋液態生物檢體、次世代定序(NGS)、數位病理、多重免疫組化、微量殘存疾病(MRD) 檢測、伴隨診斷以及人工智慧驅動的觀察解讀。這項需求源自於日益沉重的疾病負擔。根據國際癌症研究機構 (IARC) 的數據，2022 年全球新增癌症病例約 2,000 萬例，癌症相關死亡人數達 970 萬，預計到 2050 年，新增癌症病例將超過 3,500 萬例。

對於診斷方法開發商和先進檢測網路而言，領先地位越來越取決於分析有效性、臨床效用、保險報銷的合理性以及可擴展的數據基礎設施。腫瘤學相關人員優先考慮那些能夠縮短診斷時間、識別可操作的生物標記、指導標靶治療並支持長期監測，同時又不會給臨床醫生或醫療保健系統帶來過重負擔的檢測方法。

診斷領域的變革性變化

癌症診斷領域正從單一分析、依賴組織樣本的檢測方法轉向整合的多體學和縱向模型。雖然對於組織樣本有限的患者而言，液態生物檢體的重要性日益凸顯，但全面的基因組分析正被擴大用於識別各種腫瘤類型中罕見但具有治療價值的突變。數位病理學也從數位化工作流程轉向形態學、免疫背景和生物標記表達的計算評估。

人工智慧的累積影響

人工智慧（AI）正逐漸超越單一解決方案的範疇，成為貫穿癌症診斷整個價值鏈的累積動力。在病理領域，AI可以輔助進行切片分類、有絲分裂檢測、腫瘤分割以及生物標記的定量評估。在基因組學領域，機器學習有助於突變分類、分子觀察的優先排序以及基因組分析結果與臨床表現型的整合。在影像學和放射組學領域，經過充分檢驗的AI可以輔助進行病灶檢測、風險分層以及治療反應評估。

主要市場的關鍵區域洞察

亞太地區是下一代癌症診斷領域最具活力的地區之一，這主要得益於高癌症發病率、不斷擴展的定序能力以及中國、日本、韓國、澳洲和印度等國的國家級精準醫療計畫。中國和印度在大規模應用下一代癌症診斷技術方面擁有巨大的潛力，但需要製定本地化策略，以應對價格可負擔性、醫保報銷、醫院准入和法規核准流程等問題。日本、韓國和澳洲在基因組腫瘤學研究的結合應用、品質認證、臨床指引整合以及實用化則較為成熟。

影響採納的關鍵群體特定見解

在東協市場，透過公私合營投資醫院、建立區域參考實驗室、發展醫療旅遊中心以及採用跨境檢測模式，癌症檢測的可及性正在不斷擴大，但價格承受能力和共同支付仍然是影響其普及的關鍵因素。海灣合作理事會（GCC）國家正在投資基因組醫學、三級癌症中心、國家衛生計畫和數位醫療基礎設施，為符合國家醫療改革議程的高價值分子診斷創造了機會。歐盟在標準化品質標準、跨境監管協調和循證應用方面發揮著至關重要的作用，但遵守《體外醫療設備法規》（IVDR）和《一般資料保護規則》（GDPR）增加了市場准入的門檻。

主要國家精準腫瘤學的發展趨勢

美國在臨床試驗頻率、伴隨診斷開發、數位病理學應用以及先進癌症檢測商業化方面主導，但保險公司的承保範圍和證據要求仍然是決定性因素。在加拿大，公共資金評估、省級報銷決策以及公平獲取是關鍵考慮因素。同時，墨西哥和巴西隨著私人腫瘤網路和分子檢測能力的擴展，需求也不斷成長。在歐洲，英國、德國、法國、義大利和西班牙受到各自報銷流程、癌症控制計畫、生物標記檢測指南以及集中式或區域檢查室模式的影響。另一方面，俄羅斯面臨准入、進口和供應方面的限制，這可能會影響先進分子診斷平台的可用性。

為行業領導者提供的實用建議

產業領導者應優先考慮具有臨床應用價值的適應症，即下一代癌症診斷技術能夠對治療方案選擇、診斷時間、臨床試驗入組或復發監測產生可衡量的影響。證據包應包含分析表現、臨床有效性、臨床效用、衛生經濟價值以及在不同人群中的真實世界結果。將證據生成融入應用流程，並與癌症中心、病理網路、生物製藥公司和保險公司夥伴關係，可以加速科技的應用。

調查方法

下一代癌症診斷的可靠調查方法結合了二手資訊分析、一手檢驗和結構化證據整合。二手研究應包括同儕審查文獻、臨床指南、監管資料庫、癌症登記資料、保險報銷決策、專利趨勢以及世界衛生組織、國際癌症研究機構、美國食品藥物管理局、歐洲藥品管理局、美國疾病管制與預防中心和國家腫瘤機構等組織提供的公共衛生資料集。

結論

新一代癌症診斷技術正成為精準腫瘤學的核心，能夠實現早期檢測、更精確的腫瘤特徵分析、標靶治療選擇以及疾病的長期監測。具備科學可靠性、可擴展的檢測能力、符合監管要求、與保險公司認可的循證依據以及安全的數據基礎設施的機構將擁有最大的發展機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 下一代癌症診斷市場：依產品分類

  • 裝置
    • 分析器
    • 序列器
  • 試劑和耗材
  • 軟體服務

第8章 下一代癌症診斷市場：依技術分類

  • DNA微陣列
  • 晶片實驗室和逆轉錄聚合酵素鏈鎖反應（RT-PCR）
  • 次世代定序
  • 蛋白質微陣列
  • qPCR和多重PCR

第9章：下一代癌症診斷市場：依癌症類型分類

  • 乳癌
  • 結腸癌
  • 肺癌
  • 攝護腺癌

第10章 下一代癌症診斷市場：依樣本類型分類

  • 血液檢體
  • 組織切片檢查

第11章 下一代癌症診斷市場：按應用分類

  • 癌症篩檢
  • 伴隨診斷
  • 預後診斷
  • 風險評估
  • 治療監測

第12章 下一代癌症診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 下一代癌症診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 下一代癌症診斷市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agena Bioscience, Inc. by Mesa Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Akadeum Life Sciences
  • Almac Group
  • Becton, Dickinson & Company
  • Bio-Techne Corporation
  • Biological Dynamics Inc.
  • BioNTech SE
  • Castle Biosciences Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips NV
  • NeoGenomics Laboratories
  • Novartis AG
  • OPKO Health, Inc.
  • Oxford Nanopore Technologies Limited
  • Qiagen NV
  • Revvity, Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Telerad Tech
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-AD36CD898567

The Next-Generation Cancer Diagnostics Market is projected to grow by USD 37.05 billion at a CAGR of 11.26% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 17.55 billion
Estimated Year [2026] USD 19.50 billion
Forecast Year [2032] USD 37.05 billion
CAGR (%) 11.26%

Next-generation cancer diagnostics are redefining oncology by moving detection, tumor classification, therapy selection, and recurrence monitoring closer to real-time clinical decision-making. The field spans liquid biopsy, next-generation sequencing (NGS), digital pathology, multiplex immunohistochemistry, minimal residual disease (MRD) testing, companion diagnostics, and AI-enabled interpretation. Demand is supported by a clear disease burden: the International Agency for Research on Cancer reported about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with new cancer cases projected to exceed 35 million by 2050.

For diagnostic developers and advanced laboratory networks, leadership increasingly depends on analytical validity, clinical utility, reimbursement evidence, and scalable data infrastructure. Oncology stakeholders are prioritizing tests that can shorten diagnostic odysseys, identify actionable biomarkers, guide targeted therapy, and support longitudinal monitoring without overburdening clinicians or health systems.

Transformative Shifts in the Diagnostic Landscape

The cancer diagnostics landscape is shifting from single-analyte, tissue-dependent testing toward integrated multi-omic and longitudinal models. Liquid biopsy is gaining relevance for patients with limited tissue availability, while comprehensive genomic profiling is increasingly used to identify rare but actionable alterations across tumor types. Digital pathology is also moving from workflow digitization to computational assessment of morphology, immune contexture, and biomarker expression.

Regulation and evidence expectations are rising in parallel. The European Union In Vitro Diagnostic Regulation has tightened requirements for clinical evidence and post-market surveillance, while the U.S. FDA's 2024 final rule on laboratory-developed tests signals greater oversight of high-complexity diagnostics. These shifts favor organizations that can combine assay innovation with quality systems, clinical validation, cybersecurity, and transparent performance reporting.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across the cancer diagnostics value chain rather than a single point solution. In pathology, AI can support slide triage, mitosis detection, tumor segmentation, and quantitative biomarker assessment. In genomics, machine learning helps classify variants, prioritize molecular findings, and integrate genomic results with clinical phenotypes. In imaging and radiomics, AI can assist lesion detection, risk stratification, and treatment response assessment when appropriately validated.

The impact is strongest when AI is embedded into governed workflows with human oversight. Diagnostic leaders must address model drift, bias, data provenance, explainability, and interoperability with laboratory information systems and electronic health records. Regulatory-grade AI will depend on diverse training datasets, prospective validation, continuous performance monitoring, and compliance with privacy requirements such as HIPAA and GDPR.

Key Regional Insights Across Major Markets

Asia-Pacific is one of the most dynamic regions for next-generation cancer diagnostics, supported by high cancer incidence, expanding sequencing capacity, and national precision medicine programs in China, Japan, South Korea, Australia, and India. China and India present large-volume adoption opportunities but require localization strategies around affordability, reimbursement, hospital access, and regulatory pathways. Japan, South Korea, and Australia are more mature in genomic oncology adoption, quality accreditation, clinical guideline integration, and research-linked implementation.

North America remains a global innovation hub due to advanced oncology networks, FDA-authorized diagnostics, payer activity, clinical trial infrastructure, and strong biopharma investment. Europe is shaped by EU IVDR implementation, national health technology assessment, cancer screening programs, and data protection rules that influence commercialization and evidence requirements. Latin America, the Middle East, and Africa show growing demand for earlier cancer detection and precision oncology, but adoption is uneven due to infrastructure gaps, specialist shortages, laboratory concentration in major cities, and variable reimbursement coverage.

Key Group Insights Shaping Adoption

ASEAN markets are expanding access to oncology testing through public-private hospital investment, regional reference laboratories, medical tourism hubs, and cross-border testing models, though affordability and out-of-pocket spending remain major determinants of uptake. The GCC is investing in genomic medicine, tertiary cancer centers, population health programs, and digital health infrastructure, creating opportunities for high-value molecular diagnostics aligned with national health transformation agendas. The European Union is important for standardized quality expectations, cross-border regulatory harmonization, and evidence-based adoption, but compliance with IVDR and GDPR raises the bar for market entry.

BRICS countries represent scale, local manufacturing potential, and increasing demand for cost-effective precision oncology across diverse healthcare systems. G7 markets provide the strongest evidence, reimbursement, regulatory, and clinical guideline benchmarks for premium diagnostic platforms. NATO markets overlap heavily with high-income healthcare systems where cybersecurity, supply chain resilience, laboratory continuity, and trusted data exchange are increasingly relevant to laboratory modernization, digital pathology, and AI-enabled diagnostics.

Key Country Insights for Precision Oncology

The United States leads in clinical trial density, companion diagnostic development, digital pathology adoption, and commercialization of advanced oncology testing, although payer coverage and evidence requirements remain decisive. Canada emphasizes publicly funded evaluation, provincial reimbursement decisions, and equitable access, while Mexico and Brazil show rising demand through private oncology networks and expanding molecular testing capacity. In Europe, the United Kingdom, Germany, France, Italy, and Spain are influenced by national reimbursement pathways, cancer plans, biomarker testing guidelines, and centralized or regional laboratory models, while Russia faces access, import, and supply constraints that can affect availability of advanced molecular platforms.

In Asia-Pacific, China is scaling domestic sequencing, oncology innovation, and hospital-based molecular testing; India is expanding affordable diagnostics across a large patient base with growing use of NGS and liquid biopsy in metropolitan centers; and Japan supports mature precision oncology pathways through regulated genomic profiling and strong clinical adoption in specialized centers. South Korea combines digital health strength with advanced hospital systems and high oncology research intensity, while Australia benefits from robust research networks, cancer registries, public health infrastructure, and quality-led implementation of genomic testing.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically actionable indications where next-generation cancer diagnostics can demonstrate measurable impact on treatment selection, time to diagnosis, trial enrollment, or recurrence monitoring. Evidence packages should include analytical performance, clinical validity, clinical utility, health-economic value, and real-world outcomes across diverse populations. Partnerships with cancer centers, pathology networks, biopharma organizations, and payers can accelerate adoption when evidence generation is built into deployment.

Operationally, organizations should invest in interoperable platforms, sample logistics, laboratory automation, quality management systems, and secure data governance. AI-enabled diagnostics require prospective validation, bias testing, workflow integration, model monitoring, and clear clinician-facing outputs. Regional commercialization should be tailored to reimbursement maturity, regulatory expectations, data privacy rules, and local testing infrastructure rather than relying on a single global launch model.

Research Methodology

A robust research methodology for next-generation cancer diagnostics combines secondary intelligence, primary validation, and structured evidence synthesis. Secondary research should include peer-reviewed literature, clinical guidelines, regulatory databases, cancer registry data, reimbursement decisions, patent activity, and public health datasets from organizations such as WHO, IARC, FDA, EMA, CDC, and national oncology agencies.

Primary research should validate adoption barriers, pricing dynamics, test utilization, workflow needs, and procurement priorities through interviews with oncologists, pathologists, molecular laboratory directors, payers, regulatory specialists, and industry executives. Findings should be triangulated across test utilization patterns, installed laboratory capacity, cancer incidence and prevalence patterns, biomarker eligibility, reimbursement status, regulatory pathways, and competitive positioning, with assumptions reviewed for regional variance and data reliability.

Conclusion

Next-generation cancer diagnostics are becoming central to precision oncology, enabling earlier detection, more accurate tumor characterization, targeted therapy selection, and longitudinal disease monitoring. The strongest opportunities will favor organizations that unite scientific credibility, scalable laboratory operations, regulatory readiness, payer-aligned evidence, and secure data infrastructure.

As cancer incidence rises globally, the industry will increasingly reward diagnostics that are actionable, affordable, reproducible, and integrated into clinical workflows. Organizations that combine multi-omic innovation with AI governance, regional commercialization discipline, and real-world evidence generation will be best positioned to shape the future of cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Next-Generation Cancer Diagnostics Market, by Product

  • 7.1. Instruments
    • 7.1.1. Analyzers
    • 7.1.2. Sequencers
  • 7.2. Reagents & Consumables
  • 7.3. Software & Services

8. Next-Generation Cancer Diagnostics Market, by Technology

  • 8.1. DNA Microarrays
  • 8.2. Lab-on- a- chip & Reverse Transcriptase-PCR
  • 8.3. Next-generation Sequencing
  • 8.4. Protein Microarrays
  • 8.5. qPCR & Multiplexing

9. Next-Generation Cancer Diagnostics Market, by Cancer Type

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Lung Cancer
  • 9.4. Prostate Cancer

10. Next-Generation Cancer Diagnostics Market, by Sample Type

  • 10.1. Blood-Based Samples
  • 10.2. Tissue Biopsy

11. Next-Generation Cancer Diagnostics Market, by Application

  • 11.1. Cancer Screening
  • 11.2. Companion Diagnostics
  • 11.3. Prognostics
  • 11.4. Risk Assessment
  • 11.5. Therapeutic Monitoring

12. Next-Generation Cancer Diagnostics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Next-Generation Cancer Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Next-Generation Cancer Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Adaptive Biotechnologies Corporation
  • 16.3. Agena Bioscience, Inc. by Mesa Laboratories, Inc.
  • 16.4. Agilent Technologies, Inc.
  • 16.5. Akadeum Life Sciences
  • 16.6. Almac Group
  • 16.7. Becton, Dickinson & Company
  • 16.8. Bio-Techne Corporation
  • 16.9. Biological Dynamics Inc.
  • 16.10. BioNTech SE
  • 16.11. Castle Biosciences Inc.
  • 16.12. Danaher Corporation
  • 16.13. Exact Sciences Corporation
  • 16.14. F. Hoffmann-La Roche Ltd.
  • 16.15. GE HealthCare
  • 16.16. Hologic Inc.
  • 16.17. Illumina, Inc.
  • 16.18. Johnson & Johnson Services, Inc.
  • 16.19. Konica Minolta, Inc.
  • 16.20. Koninklijke Philips N.V.
  • 16.21. NeoGenomics Laboratories
  • 16.22. Novartis AG
  • 16.23. OPKO Health, Inc.
  • 16.24. Oxford Nanopore Technologies Limited
  • 16.25. Qiagen N.V.
  • 16.26. Revvity, Inc.
  • 16.27. Siemens Healthineers AG
  • 16.28. Sysmex Corporation
  • 16.29. Telerad Tech
  • 16.30. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SEQUENCERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SEQUENCERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SEQUENCERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DNA MICROARRAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DNA MICROARRAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DNA MICROARRAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LAB-ON- A- CHIP & REVERSE TRANSCRIPTASE-PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROTEIN MICROARRAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROTEIN MICROARRAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROTEIN MICROARRAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL QPCR & MULTIPLEXING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL QPCR & MULTIPLEXING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL QPCR & MULTIPLEXING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD-BASED SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD-BASED SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD-BASED SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RISK ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RISK ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RISK ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THERAPEUTIC MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 123. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 124. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. GCC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 144. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. G7 NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 151. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 152. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NATO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 166. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 167. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 173. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 174. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 180. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 195. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 201. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 208. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 209. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 215. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 222. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 223. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 236. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 237. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 243. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 244. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 250. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 251. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 257. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 258. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)